Innova Biosciences
Stage
Acquired - II | AcquiredAbout Innova Biosciences
Innova Biosciences develops, manufactures and commercializes labeling reagents that are marketed worldwide by its direct salesforce as well as through a distribution network. On November 11, 2019, Innova Biosciences was acquired by Abcam, terms of the agreement were not disclosed.
Missing: Innova Biosciences's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Innova Biosciences's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Innova Biosciences Patents
Innova Biosciences has filed 5 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/30/2014 | 6/29/2021 | Molecular biology, Biotechnology, Proteins, Immunology, Carboxylate esters | Grant |
Application Date | 5/30/2014 |
|---|---|
Grant Date | 6/29/2021 |
Title | |
Related Topics | Molecular biology, Biotechnology, Proteins, Immunology, Carboxylate esters |
Status | Grant |
Latest Innova Biosciences News
Jan 17, 2020
Friday, 17 January, 2020 Abcam , a global innovator in life science reagents and tools, has announced the successful completion of the acquisition of Expedeon ’s Proteomics and Immunology business, which includes Innova Biosciences and TGR BioSciences, as of 1 January 2020. Abcam and Expedeon say they are fully committed to providing continued access to Expedeon’s proteomics and immunology products and support so that the life science community can perform their research and development without interruption. Proteomics research requires the use of molecular labels that are covalently attached to a protein of interest to facilitate detection or purification of the protein or its binding partners. With conjugation kits for over 50 types of labels for applications across the life science industry, Expedeon’s technology supports a diverse set of labels, including enzymes, metals, oligos and fluorescent proteins. Abcam will combine the newly acquired capture and conjugation technologies with its extensive antibody and protein expertise to expand and enhance its portfolio of off-the-shelf and custom reagents and tools. The news comes two months after Abcam announced a strategic partnership with BrickBio , a biotech company specialising in site-specific protein modification, covering the use of the latter’s proprietary platform for introducing conjugation-ready sites into antibodies and other proteins in both mammalian and bacterial expression systems. “Our reputation as an innovator in the field of biological reagents, coupled with our dedicated global commercialisation infrastructure, will allow us to make these technologies readily available globally,” said Dr John Baker, SVP Product Portfolio and Innovation, Abcam. “We have had teams working on conjugation for several years and the combination of this expertise with the Expedeon portfolio and other complementary conjugation technologies, including BrickBio’s, provides a very powerful platform to enable us to deliver the precision research tools required to address the majority of life science assays used today and those emerging in the future.” Please follow us and share on Twitter and Facebook . You can also subscribe for FREE to our weekly newsletters and bimonthly magazine. Related News
Innova Biosciences Frequently Asked Questions (FAQ)
Where is Innova Biosciences's headquarters?
Innova Biosciences's headquarters is located at Babraham Hall, Cambridge.
What is Innova Biosciences's latest funding round?
Innova Biosciences's latest funding round is Acquired - II.
Who are the investors of Innova Biosciences?
Investors of Innova Biosciences include Abcam and Expedeon.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.